Form 4: Vera Therapeutics Chief Legal Officer Acquires Shares and Options

Vera Therapeutics' Chief Legal Officer, Jason S. Carter, acquired 53,000 shares of Class A Common Stock and 108,000 stock options on November 18, 2024.

Summary

• Jason S. Carter, Chief Legal Officer of Vera Therapeutics, acquired 53,000 shares of Class A Common Stock on November 18, 2024.
• These shares were acquired through restricted stock units (RSUs) under the company's 2024 Inducement Plan.
• The RSUs vest in equal quarterly installments on February 20, May 20, August 20, and November 20, starting after the vesting commencement date of November 18, 2024, contingent on continuous service.
• Mr. Carter also acquired 108,000 stock options on the same date, with an exercise price of $44.81.
• These options vest with 1/4 vesting on November 18, 2025, and the remaining 1/48 vesting monthly thereafter, also subject to continuous service.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it indicates confidence from the executive. However, it is not a major event that would significantly impact the company's outlook.

Positives

• The acquisition of shares and options by a key executive like the Chief Legal Officer can be seen as a positive sign of confidence in the company's future.
• The vesting schedule of the RSUs and stock options aligns the executive's interests with the long-term performance of the company.

Risks

• The vesting of the shares and options is contingent on continuous service, which could be a risk if the executive were to leave the company before full vesting.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• The vesting schedule for the stock options and RSUs is typical for executive compensation packages in the biotechnology industry.
• Many companies use similar vesting schedules to align executive interests with long-term company performance.
• The use of both stock options and restricted stock units is a common practice for incentivizing key personnel.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates confidence from a key executive.
• The vesting schedule of the shares and options aligns the executive's interests with the long-term performance of the company, which is beneficial for all stakeholders.

Key Dates

Keywords

Vera Therapeutics, insider trading, stock options, restricted stock units, executive compensation, Class A Common Stock, Jason S. Carter, Chief Legal Officer, Form 4